Key safety findings include: No established LD50: Researchers haven't been able to determine a lethal dose in animal models, even at doses many times higher than therapeutic ranges No observed organ toxicity: Studies examining the effects of BPC-157 on liver, kidney, heart, and other organs haven't shown toxic effects No hormonal disruption: Unlike many compounds used for recovery and healing (such as growth hormone secretagogues or anabolic agents), BPC-157 doesn't appear to alter endocrine function No tumor promotion: Studies conducted to date haven't shown that BPC-157 promotes tumor growth or increases cancer risk, though this is an area that warrants continued monitoring Stable across administration routes: Both oral and injectable BPC-157 have shown comparable safety profiles Reported Side Effects Based on clinical observations and user reports, the side effects of BPC-157 are generally mild and self-limiting: Common Side Effects (Mild, Transient) Injection site reactions: Mild redness, minor swelling, or slight discomfort at the injection site

Buteau et al., 2004
Whereas, the obesity segment will expand at a significant CAGR, with the raised adoption of GLP-1 receptor agonist along with its possession of dual action are fueling the overall market growth
The good news is the major component in these drugs mimics the effect of one of the body's very own natural weight-loss hormonesso why not let your body do the work
However, providers in other medical settings can also fail to diagnose a heart attack